Where is UCB located?

UCB is headquartered in Oakville, Canada.

Is UCB a funded company?

UCB is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does UCB rank among its competitors?

UCB ranks 1519th amongst 2809 active competitors, of which 973 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was C4 Therapeutics, which secured $25M in Jan, 2024.

Who are the top competitors of UCB?

UCB's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Juno Therapeutics. Among them, C4 Therapeutics secured the most recent funding round in January, 2024.

UCB - 2026 Company Profile & Competitors

UCB is an unfunded company based in Oakville (Canada), founded in 1928. It operates as a Manufacturer of monoclonal antibodies drugs. UCB has not raised any funding yet. The company has 2809 active competitors, including 973 funded and 695 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Juno Therapeutics.

Key Metrics

Founded Year

1928

Location

Oakville, Canada

Stage

Unfunded

Ranked

1519^th among 2809 active competitors

Similar Companies

Jazz Pharmaceuticals & 544 more

View UCB's full profile

UCB has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of UCB include Jazz Pharmaceuticals, Sana Biotechnology and Juno Therapeutics. Here is the list of Top 10 competitors of UCB, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
3rd	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
6th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
7th	Pacira 2006, Parsippany Troy Hills (United States), Public	Developer of injectable non-opioid products for post-surgical pain control	$85M	HBM Healthcare Investments, Orbimed & 6 others	72/100
8th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
9th	Harbour BioMed 2016, Shanghai (China), Public	Developer of antibody therapeutics in immunology and oncology disease	$313M	Hudson Bay Capital, GIC & 19 others	71/100
10th	iTeos Therapeutics 2011, Cambridge (United States), Acquired	Developer of immunotherapy for treating cancer	$204M	Boxer Capital, RA Capital Management & 19 others	70/100
1519th	UCB 1928, Oakville (Canada), Unfunded	Manufacturer of monoclonal antibodies drugs	-	-	31/100